Lentiviral Nucleic Acid Composition & Purity

Lentiviral Nucleic Acid Composition & Purity

Purity and safety characterization for finished lentiviral (LV) particles: Built on PacBio single-molecule long-read sequencing (HiFi/CCS), this service inventories the full nucleic acid content of full and empty particles. It quantifies the proportion of Ψ-bearing target genomes, residual production plasmids (including gag/pol), endogenous/exogenous viruses (including HERV) and host-derived sequences, as well as the differences in nucleic acid content between full and empty particles, providing single-molecule–level evidence for product purity, adventitious agent characterization and RCL risk points of interest.

1. Background

In the ideal case, lentiviral particles should package only the target genome bearing the packaging signal Ψ. Located near the 5′ end of the vector RNA, Ψ is recognized by the viral GAG protein and serves as a "shipping label" specifying which RNA is to be packaged into the particle. In practice, however, manufacturing is rarely that clean. Lentiviral particles are produced from a multi-plasmid system (transfer plasmid + packaging plasmids carrying gag/pol + envelope plasmid such as VSV-G); in principle, only the transfer plasmid carries Ψ and the packaging/envelope plasmids should not be packaged, yet residual production plasmid, human endogenous retroviruses (HERV) and other viral/cellular contaminating nucleic acids are frequently detected within particles. Counterintuitively, "empty" particles are not actually empty either: they likewise package substantial amounts of nucleic acid, simply lacking the target genome.

Vector risk assessment has historically focused almost exclusively on the "target genome," assuming that packaging is "Ψ-specific." Single-molecule sequencing reveals that the proportion of RNA that is genuinely Ψ-specifically packaged varies markedly between preparations, with the remainder largely composed of non-specifically or mis-packaged species. The implications are: residual plasmids (especially gag/pol) co-delivered into recipient cells bear on RCL risk and innate immune activation; potential transfer of HERV and exogenous sequences, and their fate and genotoxicity in recipient cells, require evaluation; and empty particles dilute functional titer, forcing higher dosing and amplifying immune and toxicity burdens. Even when gel/qPCR shows "no obvious host-genome contamination," it cannot answer the question of which nucleic acids are actually packaged within the particles and in what proportions — building a full inventory requires long-read sequencing at single-molecule resolution that can resolve both intact and chimeric sequences.

Regulatory and industry guidance for this service is clearly established. ICH Q5A(R2) (2023) explicitly encourages the introduction of NGS/high-throughput sequencing for broad-spectrum adventitious-agent detection, with scope extended to genetically engineered viral vectors and gene therapy products; the FDA guidance "Testing of Retroviral Vector-Based Human Gene Therapy Products for RCR" (Final, 2020) sets requirements for RCR/RCL testing; ICH Q6B and the FDA guidance "CMC Information for Human Gene Therapy INDs" (2020) set requirements for vector purity and impurity control; and China NMPA/CDE's "Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial)" (2022) requires investigation of modification-system–related and process-related impurities and formulation of risk-control strategies. This service provides supporting characterization for vector purity, adventitious-agent safety and RCL risk by delivering a comprehensive view of the particle nucleic acid composition.

Figure 1. Schematic of nucleic acid packaging in full vs. empty lentiviral particles.

2. Technical Principle

This service is built on PacBio HiFi single-molecule long-read sequencing, combined with multi-reference alignment and species classification strategies, to inventory the full nucleic acid content packaged within lentiviral particles. PacBio HiFi provides high per-base accuracy and ultra-long reads, enabling resolution of both intact and chimeric sequences (concatemers of mixed origin) and is well suited to reconstructing the full picture of "what is packaged and in what proportions." Full and empty particles are characterized separately at matched titers, directly revealing differences in nucleic acid content between the two. Rigorous sample pretreatment (DNase/RNase digestion to remove extra-particle contamination) combined with multi-reference alignment (customer vector and production plasmid sequences, viral databases, human genome) and careful discrimination of "free sequences vs. human-genome origin" avoids misclassification. The core workflow is as follows:

(1) Sample receipt and pretreatment

Receive full/empty particles or extracted particle nucleic acids; perform DNase/RNase digestion to remove extra-particle residual nucleic acids; then lyse and purify intra-particle nucleic acids and confirm compliance with library construction requirements.

(2) PacBio long-read library construction

Long-read libraries are prepared according to the PacBio HiFi protocol, with fragmentation strategies introduced where appropriate to improve coverage uniformity.

(3) PacBio single-molecule sequencing

Sequencing is performed on the PacBio platform to the target depth; detection sensitivity for low-abundance components can be enhanced by increasing depth as required.

(4) Bioinformatic analysis and species classification

Alignment is performed against multiple references — customer vector and production plasmid sequences, viral databases and the human genome — followed by species classification and quantification. The Ψ-positive rate, residual production plasmid (including gag/pol), HERV and other exogenous/endogenous sequences are quantified, differences between full and empty particles are assessed, and a composition profile and purity characterization report are issued.

Figure 2. Workflow of the Lentiviral Particle Nucleic Acid Composition and Purity Analysis service.

3. Technical Features and Advantages

(1) Single-molecule–level inventory resolving chimeric and intact sequences

PacBio HiFi single-molecule long reads resolve both intact sequences and chimeric sequences assembled from heterogeneous sources, addressing the blind spots and ambiguities of short-read assembly in repetitive and homologous regions.

(2) Separate characterization of full and empty particles

Separate libraries are prepared from full and empty particles at matched titers, revealing differences in nucleic acid content and directly supporting evaluation of full/empty separation processes.

(3) Careful classification against multiple references

Multi-reference alignment against customer vector/production plasmids + viral databases + human genome supports careful discrimination of "free sequences vs. human-genome origin" and avoids misclassification of sequences such as HERVs.

(4) High per-base accuracy

PacBio HiFi provides high per-base accuracy and is well suited to stable detection of low-frequency components and point mutations, yielding quantitative, locus-resolved and comparable conclusions.

(5) Alignment with regulatory focus areas

This service directly addresses the expanded scope of ICH Q5A(R2) for NGS-based broad-spectrum adventitious-agent detection, the FDA RCR/RCL guidance and the impurity-control requirements of CDE 2022, with the report framed for regulatory submission contexts.

4. Applications

Purification process development and comparison: Evaluate the effect of process steps such as empty-particle removal, exosome/microvesicle removal and residual-plasmid reduction, and guide optimization.

Purity and safety characterization: Quantify the Ψ-positive rate, residual plasmids (including gag/pol), HERV and exogenous sequence proportions, and full/empty differences.

Supporting characterization of RCL risk: Reveal residual sequences related to replication competence such as gag/pol, as supplementary evidence to statutory RCR/RCL testing.

NGS-based characterization of adventitious agents: Provide a broad-spectrum long-read readout aligned with the NGS-based adventitious-agent strategy of ICH Q5A(R2).

IND/BLA purity data: Deliver a particle nucleic acid composition panorama and quantitative, comparable evidence for the regulatory submission data package.

5. Report and Deliverables

The report provides quantitative, locus-resolved, comparable evidence of particle nucleic acid composition. Core contents include:

·Full nucleic acid composition profile of the particle: Proportion of target genome vs. non-specifically packaged sequences, including the Ψ-positive proportion (a key indicator of packaging specificity).

·Residual production plasmid detection and quantification: Proportions of transfer plasmid, packaging plasmids (including gag/pol) and envelope plasmid.

·Species classification of endogenous/exogenous sequences: Including HERV and other endogenous retroviruses, and other viral/cellular sequences with classification and quantification.

·Careful annotation of "free sequences vs. human-genome origin": Attribution rationale provided for ambiguous items.

·Full vs. empty particle differential assessment: Quantitative comparison of nucleic acid content between the two.

·Chimeric sequence indicators: Presence and proportion of concatenation events between heterogeneous sources.

·Actionable recommendations: Process optimization directions (purification strategy, plasmid removal, full/empty separation) based on the composition profile.

·Data deliverables: Complete analysis report (PDF), composition profile/species classification tables, alignment files and raw sequencing data.

6. Service Workflow

* Standard turnaround: 45–55 business days.

7. Sample Requirements

* The latest Sample Submission Guide takes precedence. This service is not applicable to severely degraded samples. Please schedule and confirm the study plan before sample submission.

8. Technical Specifications

9. References

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin. Step 4 version, 2023.

[2] ICH. Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. Current Step 4 version, 10 March 1999.

[3] ICH. Q2(R2): Validation of Analytical Procedures. Step 4 version, adopted 1 November 2023.

[4] U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER). Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up; Guidance for Industry. Final, January 2020. (Docket No. FDA-1999-D-0081)

[5] U.S. FDA, CBER. Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs); Guidance for Industry. Final, January 2020.

[6] Center for Drug Evaluation, National Medical Products Administration of China (NMPA-CDE). Technical Guideline for Pharmaceutical Research and Evaluation of Ex Vivo Gene-Modified Systems (Trial) [in Chinese]. Notice No. 31 of 2022, issued 26 May 2022.